ArticleJournal of glaucoma2026
Design and Baseline Characteristics of Participants in the Clarifying the Optimal Application of Selective Laser Trabeculoplasty (SLT) Therapy (COAST) Trial 1.
Article in Journal of glaucoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04967989 (Clarifying the Optimal Application of SLT Therapy Trial), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clarifying the Optimal Application of SLT Therapy Trial
Who cites it
1 citing paper in PubMed.
- Mid to Long-Term Outcomes of Low-Energy Selective Laser Trabeculoplasty for Primary Open Angle Glaucoma.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
prcisCOAST was designed to investigate alternate approaches to SLT to provide more effective long-term disease control without the need for alternate therapies such as medications or surgery. Methodology and baseline participant characteristics are described. PURPOSE: To describe the hypothesis and methodology for the ongoing Clarifying the Optimal Application of selective laser trabeculoplasty (SLT) therapy (COAST) Trial 1 and participants' baseline characteristics.
methodsCOAST Trial 1 is a multicenter randomized trial comparing standard-energy versus low-energy SLT as initial therapy for newly diagnosed ocular hypertension (OHT) or mild-moderate primary open angle glaucoma (POAG). The hypothesis is that 12-month survival following low-energy SLT will be noninferior to 12-month survival with standard-energy SLT.
resultsWhen enrollment ceased, 418 participants had been randomized to low-energy (n=203) or standard-energy (n=215) SLT. Demographic and clinical characteristics were similar between groups. Most participants were White (66.5% and 67.9%, respectively) or Black/African American (25.1% and 21.4%, respectively). Qualifying diagnoses were mild POAG (59.6% and 62.1%, respectively), ocular hypertension (32.8% and 30.5%), and moderate POAG (7.6% and 7.4%). Mean optical coherence tomography retinal nerve fiber layer thickness was 81.9 and 82.0 µm, respectively; mean visual field mean deviation was -1.6 dB in both groups. Mean baseline IOP was highest among eyes with ocular hypertension (24.5 and 24.4 mm Hg, respectively) and lower in eyes with mild (21.8 and 21.4 mm Hg) and moderate POAG (22.0 and 21.0 mm Hg).
conclusionsCOAST is a timely and potentially highly impactful trial that will clarify the optimal utilization of SLT for long-term glaucoma management without the need for alternative therapies such as medications or surgery. The COAST sample closely resembles the population of newly diagnosed POAG/OHT patients for whom primary SLT would be appropriate, optimizing generalizability of study results when available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.